Barra de búsqueda

Other European financing instruments

Electronic Structure Modeling with Strictly Correlated Electrons Density Functional
USVSV: Universities Supporting Victims of Sexual Violence: Training for Sustainable Services
F4E: Experimental Activities in support of the design of HCLL and HCPB TBS: liquid metal system and hydrogen/metal interfaces
FRIJUM: Causes of Bargaining Failure
Partners of UBE3A as therapeutical targets: identifying the E2 and DUB enzymes involved in Angelman Syndrome
Scientific Support for Mars Express Visual Monitoring Camera
FIRE_cci: Phase 2 of the Climate Change Initiative (GMECV)
Low Cost Wireless Interactive Electronic Platform for Modern Education Systems
INNUENDO: A novel cross-sectorial platform for the integration of genomics in surveillance of foodborne pathogens
SafeBatPaths: Fumbling in the dark - effectiveness of bat mitigation measures on roads
Evaluating the potential of targeting 2- AG hydrolytic enzymes MAGL and ABHD6 as novel therapeutic strategy in multiple sclerosis
Youth employment partnerSHIP - evaluation studies in Spain, Hungary, Italy and Poland

Other International programmes

The study on ONO-SM-362 in ceramide 1-phophate induced phenomenom

Specific programme: ONO Pharmaceuticals Cooperation Project
UPV/EHU Partner Status: Partner
UPV/EHU Supervisor: Antonio Gomez Muñoz

Project start: 07/10/2014
Project end: 30/11/2016

Brief description:
The project examines the effects of the ONO-SM-362 compound on some of the effects elicited by ceramide 1-phosphate (C1P) in pancreatic cancer cell death very efficiently. These actions lead to cell survival ultimately ending up in tumorigenesis. In addition, C1P can induce inflammatory responses, some of which may be associated to tumor promotion. The project proposes that the ONO-SM-362 compound may counteract at least some of the detrimental effects of C1P in human pancreatic cells, and may also impact inflammation through actions on macrophages.